Karin Eikmans

Louis Bolk Instituut, Driebergen-Rijsenburg, Utrecht, Netherlands

Are you Karin Eikmans?

Claim your profile

Publications (3)4.84 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to chart the experiences of homeopathic injectables prescribing practitioners with regard to safety issues and the extent in which these practitioners would feel restricted in case subcutaneously administered homeopathics were banned. This was a survey among practitioners who prescribe homeopathic injectables in 12 European countries. Data were gathered from 1693 doctors experienced in the use of homeopathic injectables for subcutaneous use. The data are based on experience with an estimated 36 million patient contacts. Of the 1693 doctors 1594 (94.2%) choose subcutaneous administration because of its therapeutic effect. 96.4% of the doctors never, very rarely, or rarely, observed any adverse reactions because of the subcutaneous form of application. The reported adverse reactions were mostly harmless (local redness, hematoma, local pain). Of the doctors, 98.1% never, very rarely, or rarely observed any adverse reactions caused by the specific homeopathic medicinal product used. In addition, 99.5% of the doctors desire homeopathic injectables for subcutaneous use to stay on the market and 89% would be severely or very severely limited in their profession if homeopathic injectables were not available. The study suggests that homeopathic injectables have a very low risk profile. A very small number of severe adverse reactions (anaphylactic reaction, feverish symptoms, aversion/anxiety against injections, and asthma) have been reported with products with a concentration higher than 1:10,000.
    The Journal of Alternative and Complementary Medicine 09/2005; 11(4):609-16. · 1.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Subchronic treatment with the selective serotonergic reuptake inhibitors (SSRIs) fluoxetine, venlafaxine and paroxetine, but not sertraline, were previously shown to specifically impair vigilance performance. The current study was designed to compare the vigilance effects of subchronic treatment with the SSRIs sertraline and citalopram in healthy volunteers, according to a placebo-controlled, double-blind, three-way cross-over design. Twenty-four healthy subjects, aged 30-50 years, of whom 21 completed the study, underwent three treatment periods of 2 weeks in which they received sertraline (50 mg on days 1-8, 100 mg on days 8-15), citalopram (20 mg on days 1-8, 40 mg on days 8-15) and placebo. Treatment periods were separated by 14 days washout periods. Vigilance performance was assessed through a 45-min Mackworth Clock Test at days 1, 8 and 15 of each treatment period. It was found that citalopram impaired vigilance performance acutely after the first 20 mg dose and subchronically after 40 mg daily doses. By contrast, no vigilance impairment was found during sertraline treatment. Sertraline is the only SSRI studied so far with no detrimental effects on vigilance. This may be due to the affinity of sertraline for the dopamine reuptake site. Because citalopram is the most specific SSRI showing this effect, it is concluded that the SSRI-induced decrement of vigilance performance is specifically associated with serotonergic reuptake inhibition.
    Journal of Psychopharmacology 02/2005; 19(1):12-20. · 3.37 Impact Factor
  • Source
    01/2003;